Background: Hydroxyurea is the most accessible disease-modifying therapy for sickle cell disease (SCD), but in many low- and middle-income countries its real-world benefit is constrained by gaps in awareness, uptake, continuity, and adherence. We analyzed the full hydroxyurea pat...
Open access
Research Article10.9734/ibrr/2026/v17i2382
Background: Haematological malignancies are a heterogeneous group of clonal neoplastic disorder of the blood and blood forming organs associated with significant mortality and morbidity in our locality. Objectives: To determine the prevalence, pattern of distribution and yearly t...
Open access
Research Article10.9734/ijr2h/2025/v8i2200
Kaladada Ibitrokoemi Korubo, Akpevwe Deborah Maduka, Emmanuel Wobo, Paxman Dandyson Uku, Uchechukwu Prince Okite & Chijioke Adonye Nwauche·International Research Journal of Oncology·2026
Background: Chronic lymphocytic leukaemia (CLL) outcomes in low-resource settings are shaped not only by disease biology, but also by delayed diagnosis, limited access to therapeutic options, and treatment interruptions due to social and financial reasons. However, data describin...
Open access
Research Article10.9734/irjo/2026/v9i1202
Kaladada Ibitrokoemi Korubo, Linda Anucha Dublin-Green, Paxman Uku, Onodingene Nkemsinachi Mary-Anne, Akpevwe Deborah Maduka, Emmanuel Wobo, Uchechukwu Prince Okite, Chidiadi Ezenwa-Ahanene & Chinyere Eunice Eze·International Journal of Research and Reports in Hematology·2025
Background: Acute lymphoblastic leukaemia (ALL) is a clonal haematological malignancy characterized by the rapid proliferation of lymphoblasts which mostly affects children however, it also occurs in adults. The pathogenesis of ALL is multifactorial involving genetic and environm...
Open access
Research Article10.9734/ijr2h/2025/v8i1177